Italian and North American dietary intake after ivacaftor treatment for Cystic Fibrosis Gating Mutations.
Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment.
Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1.
Rate and Predictors of Prescription of Lumacaftor – Ivacaftor in the 18 Months Following Approval in the United States
Assessing Differences in Mortality Rates and Risk Factors Between Hispanic and Non-Hispanic Patients With Cystic Fibrosis in California.
